Immune thrombocytopenia (ITP) trials in Romania
6 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peoplePhase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
- Where
- Bucharest, Cluj-Napoca
- Age
- 18 years and over
- People
- 78 worldwide
- Run by
- Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00 - Phase 3Taking peopleA Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- Where
- Bucharest, Cluj-Napoca, Craiova
- Age
- 18 years to 70 years
- People
- 40 worldwide
- Run by
- Kedrion S.p.A.
See details and how to joinNCT07059000 · EU 2023-507115-35-00 - Phase 2/3Taking peopleA Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
- Where
- Bucharest
- Age
- 12 years to 17 years
- People
- 24 worldwide
- Run by
- argenx
See details and how to joinNCT07194850 · EU 2025-521055-23-00 - Phase 1Taking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Bucharest, Cluj-Napoca
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - Phase 1Enrolling by invitationPhase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Where
- Bucharest, Cluj-Napoca
- Age
- 18 years to 85 years
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06723106 - Phase 3Taking peopleA Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Where
- Bucharest, Sibiu, Târgu Mureş
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- argenx
See details and how to joinNCT06544499 · EU 2024-515451-38-00